Haoxi Health Technology Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing, dated June 4, 2026, reports on an Extraordinary General Meeting (EGM) of shareholders held on June 2, 2026, in Beijing, China. The meeting addressed significant corporate governance and capital structure changes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder voting results regarding capital structure.
Material Changes and Voting Results
Shareholders approved several resolutions with overwhelming support. The voting breakdown for Class A and Class B shares (voting together) was as follows:
- Share Capital Increase: Approved to increase authorized share capital from US$384.25 million to US$35.2 trillion. This involves increasing Class A shares to 100 trillion and Class B shares to 10 trillion. Votes: 10,012,410 For, 25,655 Against, 42 Abstain.
- Eighth Amended M&AA: Approved to reflect the capital increase and quorum changes. Votes: 10,015,954 For, 21,230 Against, 923 Abstain.
- Share Consolidation Authorization: Approved to authorize the Board to consolidate shares at a ratio between 1-for-2 and 1-for-8,000 within two years. Votes: 10,012,123 For, 25,283 Against, 701 Abstain.
- Further Amendment to M&AA: Approved to reflect potential share consolidation. Votes: 10,012,378 For, 25,592 Against, 137 Abstain.
- Adjournment Proposal: Approved to allow for further proxy solicitation if necessary. Votes: 10,017,780 For, 20,113 Against, 214 Abstain.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial outlook, risks, or contingencies. The primary operational risk noted is the potential for significant dilution or share price volatility resulting from the authorized share consolidation (up to 1-for-8,000) and the massive increase in authorized share capital.
Investor Verification Checklist
- Verify the exact implementation date and ratio for the Share Consolidation, as the Board retains discretion within the 1-for-2 to 1-for-8,000 range.
- Confirm the regulatory approval status for the increase in authorized share capital to US$35.2 trillion.
- Review the Eighth Amended Memorandum and Articles of Association for specific changes to quorum requirements and shareholder rights.
- Monitor future filings for the actual execution of the share consolidation and any resulting impact on share price and liquidity.